Key Points
- Director Cynthia L. Lucchese bought 1,784 shares at an average price of $84.06 on Dec. 22, raising her holding by about 23% to 9,445 shares (≈$794k).
- The board has authorized a $2.00 billion share repurchase program, permitting the company to buy up to roughly 15.4% of outstanding shares.
- CooperCompanies appointed Walter M. Rosebrough Jr. to the board and entered a cooperation agreement with Browning West, indicating activist engagement and potential near‑term governance or strategic changes.
The Cooper Companies, Inc. (NASDAQ:COO - Get Free Report) Director Cynthia Lucchese purchased 1,784 shares of the firm's stock in a transaction on Monday, December 22nd. The stock was bought at an average cost of $84.06 per share, with a total value of $149,963.04. Following the completion of the purchase, the director owned 9,445 shares of the company's stock, valued at approximately $793,946.70. This represents a 23.29% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Cooper Companies Price Performance
COO stock opened at $82.88 on Wednesday. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.89 and a quick ratio of 1.13. The company's 50-day moving average is $75.22 and its 200-day moving average is $72.23. The stock has a market capitalization of $16.24 billion, a PE ratio of 44.09, a price-to-earnings-growth ratio of 2.39 and a beta of 1.05. The Cooper Companies, Inc. has a 1 year low of $61.78 and a 1 year high of $100.24.
Cooper Companies (NASDAQ:COO - Get Free Report) last posted its quarterly earnings results on Thursday, December 4th. The medical device company reported $1.15 earnings per share for the quarter, topping analysts' consensus estimates of $1.11 by $0.04. Cooper Companies had a return on equity of 10.02% and a net margin of 9.16%.The business had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.06 billion. During the same period in the prior year, the business earned $1.04 EPS. The firm's revenue for the quarter was up 4.6% on a year-over-year basis. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. Equities research analysts expect that The Cooper Companies, Inc. will post 3.98 EPS for the current fiscal year.
Cooper Companies declared that its Board of Directors has initiated a share repurchase program on Wednesday, September 17th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the medical device company to purchase up to 15.4% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company's leadership believes its shares are undervalued.
Wall Street Analyst Weigh In
A number of research firms have weighed in on COO. Robert W. Baird raised their price objective on shares of Cooper Companies from $85.00 to $98.00 and gave the company an "outperform" rating in a research note on Friday, December 5th. Weiss Ratings restated a "sell (d+)" rating on shares of Cooper Companies in a report on Monday. Needham & Company LLC reaffirmed a "buy" rating and issued a $100.00 price target (up previously from $94.00) on shares of Cooper Companies in a research report on Friday, December 5th. Barclays reissued an "overweight" rating and set a $91.00 price objective on shares of Cooper Companies in a report on Monday, December 8th. Finally, The Goldman Sachs Group reissued a "sell" rating and issued a $71.00 price objective (up from $64.00) on shares of Cooper Companies in a research note on Monday, December 8th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $90.15.
Get Our Latest Research Report on Cooper Companies
Key Cooper Companies News
Here are the key news stories impacting Cooper Companies this week:
- Positive Sentiment: Board refresh and governance alignment — CooperCompanies appointed Walter M. Rosebrough Jr., former STERIS CEO, as an independent director effective Jan. 3, 2026 and entered a cooperation agreement with Browning West that includes board‑refresh commitments (Browning West will support the board slate and Rosebrough may be considered for Chair by end‑2026). This brings deep medical‑device and operational experience and signals constructive engagement with a large shareholder, which can be a catalyst for strategic / operational improvements. CooperCompanies Appoints Walter M Rosebrough, Jr to its Board of Directors
- Positive Sentiment: Insider buying — Director Cynthia L. Lucchese purchased 1,784 shares at an average price of $84.06 on Dec. 22, increasing her holding by ~23%. Insider purchases can be read as a signal of confidence from management/board and may support near‑term investor sentiment. SEC Filing — Insider Purchase
- Neutral Sentiment: Details and filings — The cooperation agreement and Rosebrough appointment will be filed in an 8‑K; Browning West agreed to customary standstill and voting commitments. These legal/filing items formalize the arrangement but do not immediately change fundamentals. Press Release / 8‑K Disclosure
- Neutral Sentiment: Unrelated market items — Several other news items in the feed (mining/Ring of Fire, crypto partnerships, regional development stories) are unrelated to CooperCompanies’ operations and unlikely to influence COO’s near‑term stock move. Unrelated Market News
- Negative Sentiment: Activist/pressure risk — While the cooperation agreement is constructive, Browning West’s involvement signals prior shareholder dissatisfaction and introduces potential near‑term uncertainty around governance and strategy execution (board turnover, revised capital allocation priorities). Some investors may view this as a governance risk until the board refresh and strategic actions prove value accretive. Quiver Quant — Cooperation Agreement Summary
Institutional Investors Weigh In On Cooper Companies
A number of institutional investors have recently added to or reduced their stakes in the company. Bell Investment Advisors Inc boosted its stake in shares of Cooper Companies by 106.3% in the 3rd quarter. Bell Investment Advisors Inc now owns 425 shares of the medical device company's stock worth $29,000 after buying an additional 219 shares during the last quarter. J.Safra Asset Management Corp increased its position in shares of Cooper Companies by 204.8% during the second quarter. J.Safra Asset Management Corp now owns 506 shares of the medical device company's stock valued at $36,000 after acquiring an additional 340 shares during the last quarter. CYBER HORNET ETFs LLC bought a new stake in Cooper Companies during the second quarter worth $36,000. GKV Capital Management Co. Inc. purchased a new position in Cooper Companies in the first quarter worth $40,000. Finally, MUFG Securities EMEA plc purchased a new position in Cooper Companies in the second quarter worth $42,000. 24.39% of the stock is owned by institutional investors.
Cooper Companies Company Profile
(
Get Free Report)
Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women's health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.
The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
